Amgenvs.Moderna
AMGN vs MRNA · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Amgen is about 2.5× larger than Moderna by market cap; year to date, Moderna leads (+568.0% vs +26.2%).
Side by side
| AMGN | MRNA | |
|---|---|---|
| Market cap | $220B | $88.6B |
| Price | $414.87 | $225.00 |
| Today | +1.8% | +14.2% |
| Return YTD | +26.2% | +568.0% |
| Return 1Y | +39.8% | +605.6% |
| Since June 26, 2026 | +15.8% | +234.5% |
| P/E | 25.2 | — |
| P/S | 5.8 | 39.8 |
| P/B | 18.8 | 13.1 |
Data as of 2026-10-09 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
AmgenAMGN
Long-established in biotech, with oncology and haematology at the centre of the portfolio, immunology beside it and a line in bone disease. MariTide is the obesity candidate in the pipeline.
Full AMGN profile →ModernaMRNA
Built on mRNA, the technology behind its covid vaccine. The pipeline pushes the same platform into further vaccines and into oncology.
Full MRNA profile →More AMGN & MRNA comparisons
Other head-to-heads in the Biotech & innovation segment.